Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CHILDREN S CLARITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CHILDREN S CLARITIN.
BROMPHENIRAMINE MALEATE vs CHILDREN'S CLARITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Loratadine is a long-acting second-generation antihistamine that selectively antagonizes peripheral histamine H1 receptors, thereby inhibiting the effects of histamine released from mast cells and basophils, reducing allergic symptoms.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
10 mg orally once daily
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
The terminal elimination half-life of loratadine is 8-14 hours (mean 11 hours) in healthy adults; for the active metabolite descarboethoxyloratadine, half-life is 17-24 hours (mean 20 hours). This supports once-daily dosing.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Loratadine is primarily eliminated via hepatic metabolism, with approximately 80% of the dose excreted as metabolites in urine (40%) and feces (40%). Less than 1% is excreted unchanged in urine.
Category C
Category C
Antihistamine
Antihistamine